Related Experiment Video
Updated: May 5, 2026
10:35
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
2.7K
Diabetes in Europe: an update
T Tamayo1, J Rosenbauer1, S H Wild2
1Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Diabetes Research and Clinical Practice
|December 5, 2013
Summary
Diabetes prevalence is rising in Europe, impacting millions and increasing healthcare costs. Addressing modifiable risk factors and improving diabetes management are crucial for public health in the region.
Area of Science:
- Public Health
- Epidemiology
- Endocrinology
Background:
- Diabetes is a leading cause of death in the IDF Europe Region (EUR), with significant disability and healthcare costs.
- In 2013, an estimated 56 million people had diabetes in EUR, representing an 8.5% prevalence, with wide country variations.
Purpose of the Study:
- To analyze diabetes prevalence, trends, and risk factors in the IDF Europe Region.
- To highlight challenges in diabetes management and suggest strategies for improvement.
Main Methods:
- Data synthesis from existing epidemiological studies and registries within the IDF Europe Region.
- Analysis of prevalence estimates, trends, and risk factor distributions across diverse European countries.
Main Results:
- Diabetes prevalence varied significantly across EUR countries in 2013, from 2.4% in Moldova to 14.9% in Turkey.
- A projected increase of nearly 10 million diabetes cases by 2035 in EUR.
- Type 1 diabetes incidence in children (0-14 years) has also risen, with 129,350 cases in 2013.
Conclusions:
- Modifiable risk factors like obesity, inactivity, and smoking require targeted interventions to reduce type 2 diabetes incidence.
- Enhanced professional networking, patient empowerment, and quality monitoring are essential for effective diabetes management in Europe.
More Related Videos
Related Concept Videos
01:26Diabetes Mellitus: Introduction
24
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and...
24
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:19Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
01:26Type I Diabetes II: Pathophysiology
75
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75